High-Dose Sliding-Scale Insulin: Do Not Use as Monotherapy
Sliding-scale insulin alone is strongly discouraged for hospitalized type 2 diabetic patients who are NPO—you must use a basal-plus regimen instead. 1, 2, 3, 4
Why Sliding-Scale Monotherapy Fails
- Sliding-scale insulin treats hyperglycemia reactively after it occurs, causing wide glycemic swings and perpetuating poor control 5, 4
- When used alone in established type 2 diabetes, it leads to clinically significant hyperglycemia in the majority of patients 4, 6
- Compared to basal-bolus regimens, sliding-scale monotherapy is associated with higher rates of post-operative wound infection, pneumonia, bacteremia, and acute renal/respiratory failure 4
- Multiple guidelines from the American Diabetes Association, VA/DoD, and AACE condemn its use as monotherapy 1, 2, 3, 4
The Correct Approach: Basal-Plus Regimen for NPO Patients
For a hospitalized type 2 diabetic patient who is NPO, use basal insulin with correction doses—never correction doses alone. 2, 3, 4
Initial Basal Insulin Dosing
- Start with 0.2 U/kg/day of long-acting insulin (glargine or detemir) given once daily 4
- For a typical 70-kg patient, this equals 14 units per day 4
- Administer 100% of the calculated dose as basal insulin since the patient is NPO 4
High-Dose Correction Scale (Added to Basal Insulin)
Use these correction doses of rapid-acting insulin (aspart, lispro, or glulisine) every 6 hours while NPO: 7, 4
| Blood Glucose (mg/dL) | Correction Dose |
|---|---|
| 150–200 | 2 units |
| 201–250 | 4 units |
| 251–300 | 6 units |
| 301–350 | 8 units |
| >350 | 10 units + notify physician |
Critical caveat: These correction doses are appropriate only when basal insulin is already prescribed—never use them alone 4
Dose Adjustments for High-Risk Patients
Reduce the initial basal dose by 50% (use 0.1 U/kg/day instead) if the patient has: 4
- Age ≥65 years 4
- Renal insufficiency (eGFR <60 mL/min) 4
- History of severe hypoglycemia 4
- Severe malnutrition or low albumin 6
For a 70-kg elderly patient with renal disease, start with 7 units of basal insulin daily instead of 14 units 4
Daily Titration Algorithm
Days 1-2: Monitor Response
Day 3 Onward: Adjust Basal Dose
- If correction insulin is needed >2 times per day: Increase basal insulin by 10-20% 4
- If hypoglycemia occurs (<70 mg/dL): Reduce basal insulin by 20% 4
- Target pre-meal/fasting glucose: 140-180 mg/dL 8, 2, 3
When Sliding-Scale Alone Might Be Acceptable (Not This Patient)
The only situations where correction insulin without basal insulin may be used: 4, 9
- Stress hyperglycemia in patients without established diabetes 7, 4
- Admission glucose <180 mg/dL with HbA1c <7% on diet alone 9
- Short-term steroid-induced hyperglycemia in non-diabetics 4
Your patient does not meet these criteria because they have established type 2 diabetes requiring treatment 4
Evidence Strength
The 2025 ADA Standards of Care explicitly state that basal insulin or basal-plus-correction is the preferred treatment for NPO patients 2, 3. The 2017 VA/DoD guideline demonstrates that sliding-scale monotherapy results in worse glycemic control and more treatment failures than basal-based regimens 1. A 2021 Lancet review confirms that sliding-scale alone should be discouraged except in the narrow circumstances above 7.
Common Pitfalls to Avoid
- Never continue sliding-scale monotherapy beyond admission orders—this perpetuates poor control 4
- Do not use premixed insulin (70/30) in hospitalized patients—it causes unacceptably high hypoglycemia rates 7, 4
- Avoid holding basal insulin even when the patient is NPO—this is especially critical in type 1 diabetes but applies to insulin-requiring type 2 diabetes as well 2, 3
- Do not administer correction doses without confirming basal insulin is ordered 4
Hypoglycemia Risk Trade-Off
Basal-bolus regimens carry a 4-6 fold higher risk of hypoglycemia (RR 5.75 for glucose ≤70 mg/dL) compared to sliding-scale monotherapy 7, 4. However, the superior glycemic control achieved with basal insulin results in lower overall morbidity and mortality despite this increased hypoglycemia risk 4, 10. The basal-plus approach (basal insulin with correction doses only, no scheduled prandial insulin) offers a middle ground with better control than sliding-scale alone and less hypoglycemia than full basal-bolus 7, 4.